Denham Samuel, Koppelman Gerard H, Blakey John, Wjst Matthias, Ferreira Manuel A, Hall Ian P, Sayers Ian
Division of Therapeutics & Molecular Medicine, University Hospital of Nottingham, Nottingham, UK.
Respir Res. 2008 Apr 28;9(1):38. doi: 10.1186/1465-9921-9-38.
Asthma and allergy are complex multifactorial disorders, with both genetic and environmental components determining disease expression. The use of molecular genetics holds great promise for the identification of novel drug targets for the treatment of asthma and allergy. Genome-wide linkage studies have identified a number of potential disease susceptibility loci but replication remains inconsistent. The aim of the current study was to complete a meta-analysis of data from genome-wide linkage studies of asthma and related phenotypes and provide inferences about the consistency of results and to identify novel regions for future gene discovery.
The rank based genome-scan meta-analysis (GSMA) method was used to combine linkage data for asthma and related traits; bronchial hyper-responsiveness (BHR), allergen positive skin prick test (SPT) and total serum Immunoglobulin E (IgE) from nine Caucasian asthma populations.
Significant evidence for susceptibility loci was identified for quantitative traits including; BHR (989 pedigrees, n = 4,294) 2p12-q22.1, 6p22.3-p21.1 and 11q24.1-qter, allergen SPT (1,093 pedigrees, n = 4,746) 3p22.1-q22.1, 17p12-q24.3 and total IgE (729 pedigrees, n = 3,224) 5q11.2-q14.3 and 6pter-p22.3. Analysis of the asthma phenotype (1,267 pedigrees, n = 5,832) did not identify any region showing genome-wide significance.
This study represents the first linkage meta-analysis to determine the relative contribution of chromosomal regions to the risk of developing asthma and atopy. Several significant results were obtained for quantitative traits but not for asthma confirming the increased phenotype and genetic heterogeneity in asthma. These analyses support the contribution of regions that contain previously identified asthma susceptibility genes and provide the first evidence for susceptibility loci on 5q11.2-q14.3 and 11q24.1-qter.
哮喘和过敏是复杂的多因素疾病,其疾病表现由遗传和环境因素共同决定。分子遗传学的应用为识别治疗哮喘和过敏的新型药物靶点带来了巨大希望。全基因组连锁研究已确定了一些潜在的疾病易感位点,但重复性研究结果仍不一致。本研究的目的是对哮喘及相关表型的全基因组连锁研究数据进行荟萃分析,推断结果的一致性,并确定未来基因发现的新区域。
采用基于秩次的全基因组扫描荟萃分析(GSMA)方法,合并来自九个白种人哮喘群体的哮喘及相关性状的连锁数据;支气管高反应性(BHR)、过敏原阳性皮肤点刺试验(SPT)和血清总免疫球蛋白E(IgE)。
确定了定量性状易感位点的显著证据,包括:BHR(989个家系,n = 4294)位于2p12-q22.1、6p22.3-p21.1和11q24.1-qter;过敏原SPT(1093个家系,n = 4746)位于3p22.1-q22.1、17p12-q24.3;总IgE(729个家系,n = 3224)位于5q11.2-q14.3和6pter-p22.3。哮喘表型分析(1267个家系,n = 5832)未发现任何具有全基因组显著性的区域。
本研究是首次进行的连锁荟萃分析,以确定染色体区域对哮喘和特应性疾病风险的相对贡献。定量性状获得了几个显著结果,但哮喘未获得,这证实了哮喘表型和遗传异质性增加。这些分析支持了包含先前确定的哮喘易感基因区域的贡献,并为5q11.2-q14.3和11q24.1-qter上的易感位点提供了首个证据。